Previous studies have shown that patients continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on the day of surgery are more likely to have significant intraoperative hypotension, higher rates of postoperative acute kidney injury, and lower incidences of postoperative atrial fibrillation. However, many of these studies were prone to bias and confounding, and questions remain over the validity of these outcomes. This observational, before-and-after quality improvement audit aimed to assess the effect of withholding these medications on the morning of surgery. We recruited 323 participants, with 83 (26%) having their preoperative angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) withheld on the day of surgery. There were only very small Spearman rank-order correlations between time since last dose of these medications (rho -0.12, P=0.057) and intraoperative and recovery room intravenous fluid administration (rho -0.11, P=0.042). There was no statistically significant difference between the continued or withheld groups in vasopressor (metaraminol use 3.5 [1.5-8.3] mg versus 3.5 [1.5-8.5] mg, P=0.67) or intravenous fluid administration (1000 ml [800-1500] ml versus 1000 [800-1500] ml, P=0.096), nor rates of postoperative acute kidney injury (13% vs 18%, P=0.25) or atrial fibrillation (15% versus 18%, P=0.71). This audit found no significant differences in measured outcomes between the continued or withheld ACEi/ARB groups. This finding should be interpreted with caution due to the possibility of confounding and an insufficient sample size. However, as the finding is in contrast to many previous studies, future prospective randomised clinical trials are required to answer this important question.
In 2011, 3.7 million Australians had documented cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEi) (35%) 1 , and angiotensin II receptor blockers (ARBs) (27%) were frequently used for treatment. With the growing epidemic of metabolic syndrome and cardiovascular risk factors, more and more patients will be receiving these medications and with about 1 in 10 Australians having major surgery annually 2 , their optimal management is of paramount importance.
Hypotension at, or shortly after, induction of anaesthesia in patients who have preoperative antagonism of their reninangiotensin-aldosterone system is commonly observed, whether by a decrease in blood pressure [3] [4] [5] [6] or increased requirement of support with vasoconstrictors 3,5-11 , although this finding has been somewhat mixed 12, [13] [14] [15] [16] .
Acute kidney injury (AKI) occurs in 5-42% of patients who undergo cardiac surgery depending on the definition of renal dysfunction used 17 . Even small increases in serum creatinine postoperatively are associated with increased mortality 17 , longer intensive care unit (ICU) and hospital stay [18] [19] [20] [21] and increased need for dialysis 22, 23 . The impact of ACEi on renal failure in cardiac surgery is widely studied but results are conflicting, with studies finding an increased risk of postoperative AKI with preoperative use of ACEi/ARB 7, 8, 24, 25 , while others have not 3, 5, 9, 19, 26 . The largest retrospective study conducted recently actually found a protective effect of preoperative ACEi use on rates of AKI, although this was only found for patients requiring dialysis to treat the dysfunction 27 .
Atrial fibrillation (AF) occurs in 20-50% of patients following cardiac surgery [28] [29] [30] [31] , with incidence peaking on the second postoperative day 32 . Postoperative AF leads to prolonged hospital length of stay 33 , higher hospital costs [33] [34] [35] [36] and increased in-hospital and 4-year mortality 37, 38 . Although primarily self-limiting, greater prevalence of haemodynamic instability and thromboembolic events is seen in patients with AF 29 . The impact of preoperative ACEi/ARB therapy on postoperative AF in cardiac surgery is also unclear, with studies finding either a protective role 39 , no effect 3, 38, 40, 41 or an increased risk 7, 8, 24, 42 .
While the evidence to continue or withhold ACEi/ARB therapy before surgery is limited, the balance of current evidence suggests protective effects perioperatively are minimal and that the withholding of the immediate preoperative dose may be prudent, particularly in patients with other risk factors for hypotension 16 . In this context, we conducted a quality improvement audit before and after implementation of this policy in order to characterise the risk of haemodynamic instability and adverse perioperative outcomes associated with use or omission of ACEi/ARB therapy. This was a prospective, observational, before-and-after audit conducted at a large tertiary teaching hospital and a smaller outer-suburban hospital in metropolitan Melbourne. The active recruitment phase was six months. The preassessment clinic (PAC) policy was changed in the latter three months of recruitment in the large tertiary teaching hospital to withholding ACEi or ARB on the day of surgery. The PAC policy advised withholding ACEi/ARB therapy on the morning of surgery for patients: (i) undergoing major surgery with expected duration of surgery greater than two hours; (ii) with expected intraoperative fluid administration greater than two litres; (iii) with expected hospital stay of two days or more, or (iv) expected to go directly to the intensive care unit or the high dependency unit postoperatively. Patients with known cardiac failure or minor/intermediate surgery were not instructed to stop their ACEi/ARB. In addition, if the PAC anaesthetist deemed it clinically appropriate, patients had their ACEi or ARB continued. No patients had their management influenced by being involved in the audit.
Materials and methods
Inclusion criteria for the audit were all patients on chronic, daily treatment with ACEi/ARBs undergoing elective or non-urgent surgery; the latter defined as those undergoing surgery at least 12 hours from admission (thus providing an opportunity to withhold medications). Exclusion criterion was emergency surgery within 12 hours of admission.
Patients were enrolled on the morning of their surgery and followed up until discharge from hospital. We collected demographic, surgical, anaesthetic, and other perioperative data. The primary endpoint of the study was hypotension as defined by the minimum systolic blood pressure following induction of anaesthesia, as well as metaraminol dose and intravenous fluid dose. The secondary endpoints were AKI, defined as a 50% or 26.4 μmol/l increase in serum creatinine postoperatively (as defined by the AKIN criteria 43 ), and AF, confirmed by electrocardiogram. Intraoperative data were recorded onto a case report form by the primary anaesthetist, who was not blinded to ACEi/ARB treatment cessation. AKI was detected using a ratio of postoperative peak in-hospital creatinine levels to preoperative baseline levels.
The sample size for this study was based on 80% power to identify a one-third (or greater) reduction in the incidence of hypotension from 60% to 40% (two-tailed = 0.05); this required at least 95 patients to be enrolled in each group.
The statistical software package, Statistical Product and Service Solutions v.20 for Windows, was used for statistical analysis. Means of the two groups were compared using unpaired Student's t-tests and Mann-Whitney U test for nonnormally distributed means, while comparisons of categorical data were done using Pearson chi-square tests. Spearman rank-order correlation was also utilised for non-parametric correlation analysis in addition to multiple regression analysis.
Results
A total of 323 patients were enrolled in this audit. Of these, 83 patients (26%) had their ACEi/ARB medication withheld and 240 patients (74%) continued. The mean time from last dose to start of surgery in the continued group was 5.6 (4.5) hours, compared with 28 (10) hours in the withheld group; P <0.0005.
Patient demographics, results of investigations and surgical characteristics are reported in Table 1 . Due to the low prevalence of some surgical specialties, they have been combined into the grouping "other surgery." These specialties were urology, ear, nose and throat surgery, oral and maxillofacial surgery, ophthalmology, burns and trauma surgery. There were more patients in the withheld group who were undergoing cardiac surgery than in the continued group (Table 1) .
Intraoperative observations are reported in Table 2 . The groups were similar in regard to anaesthetic drugs administered, intraoperative vital signs, urine output, and duration of surgery.
There was no statistically significant difference between the groups in vasopressor (metaraminol dose 3.5 [1.5-8.3] mg versus 3.5 [1.5-8.5] mg), intraoperative fluid (1000 ml [800-1500] ml versus 1000 [800-1500] ml) or lowest intraoperative systolic blood pressure for the continued and withheld groups, respectively ( Table 2 ). In view of the imbalance in American Society of Anesthesiologists (ASA) physical status and elective surgery status, multiple linear regression adjusted for ASA score and elective surgery status found no significant association between ACEi/ARB status and metaraminol dose or IV fluid therapy. Due to the non-normative distribution of metaraminol dose and IV fluid administration, they were recalculated according to non-parametric Spearman rank correlation. We compared the number of hours from the last dose of ACEi or ARB to the dependent variables of metaraminol dose (rho -0.12, P=0.057) and IV fluid therapy (rho -0.13, P=0.024). There was no statistically significant difference between the groups in rates of postoperative AKI (13% versus 18%) or AF (15% versus 18%) for the continued and withheld groups, respectively.
Discussion
Our primary aim was to characterise the effect of withholding versus continuing ACEi/ARB on the incidence of hypotension, and associated vasopressor and fluid administration. We found no statistically significant differences in intraoperative blood pressure, vasopressor use or fluid administration between the two groups.
We did not identify any significant differences in the rates of postoperative AKI or AF.
This study's strength lies in that it is among a limited number of studies that have recorded the actual time from the last dose of ACEi/ARB to the start of surgery, allowing for accurate comparisons to be made. Broad inclusion criteria and the dual-centred design provide greater generalisability. Data were collected according to a prospective study protocol, while most previous other studies have collected data retrospectively.
As an observational study, the limitations of this audit should be recognised. Patients were not randomly assigned to groups, which introduced the possibility of selection bias and confounding. In the first three months, there were patients who had their preoperative ACEi/ARB withheld, while in the latter three months, there were patients who were still having these drugs continued preoperatively as a result of the preferences of individual anaesthetists. These choices could be reflective of specific scenarios in which it is more favourable to have an ACEi/ARB discontinued, such as higher risk surgery where hypotension and major fluid shifts are to be expected. Other possible limitations are that the anaesthetic technique, blood pressure management strategy or preoperative medication regimens were not standardised. As such, there may be variations in care patterns or clinical decisions that underlie the observed data and confound the conclusions of the present study. The continued group had more patients who were having elective surgery, as well as having a significantly lower ASA physical status score, suggesting that the patients in this group were healthier and may have required less intraoperative fluids and vasopressors. Thus, it is possible that this imbalance served to hide the true result of a significant difference between the two groups. A discrepancy between the groups also existed in the type of surgery they were having, with a greater proportion of the withheld group undergoing cardiac surgery. Finally, there were limitations in data collection, as intraoperative data were collected by the primary anaesthetist based on charted observations. Previous studies have shown these data to be of variable quality [44] [45] [46] [47] [48] .
Given that patients undergoing cardiac surgery would typically require more metaraminol, the greater proportion of cardiac patients in the withheld group could account, therefore, for the absence of significant difference across all surgeries. This could also perhaps explain the significant results found by previous randomised trials as they only looked at patients undergoing vascular surgery 49, 50 . A Unless listed otherwise, values are number (%) of patients. ACEi=angiotensin-converting enzyme inhibitor; AF=atrial fibrillation; ARB=angiotensin II receptor blocker; ASA=American Society of Anesthesiologists; BSL=blood sugar level; COPD=chronic obstructive pulmonary disease; SD, standard deviation; TIA=transient ischaemic attack; IQR=interquarltile range. significant result for vasopressor use in non-cardiac surgery has been found when ACEi or ARBs were taken with diuretics, suggesting that concomitant medication may have an effect on this result as well 51 . Our exploratory analysis found a negative correlation between time from last ACEi/ ARB dose and total fluid administration intraoperatively and postoperatively. Although the correlation was weak, it may suggest that ACEi and ARB have an effect that is clinically important, at least in some patients. This is in accordance with other data showing that 10 hours is the minimal time period between last dose of ACEi or ARB to the start of surgery needed in order to reduce the risk of intraoperative hypotension 52 . The greater proportion of patients undergoing cardiac surgery 53 combined with the higher ASA physical status 54 in the withheld group probably confounded risk assessment of postoperative AKI and AF, thus potentially masking an effect. No study previously has actually looked at the effect of withholding ACEi/ARB on the day of surgery on rates of postoperative AKI or AF. Up to now, only two studies, both observational, have assessed renal failure in non-cardiac surgery 26, 55 . The number of patients undergoing cardiac surgery in our study was small. It may be that AKI is only associated with ACEi/ARB use in cardiac surgery, or it may be that there was insufficient power to demonstrate this effect in a non-cardiac population. To our knowledge, this is the first study to assess the the effect of withholding these medications on the incidence of postoperative AF in noncardiac surgery, and although our results do not align with the one randomised trial assessing AF, cardiopulmonary bypass is a known risk factor for the postoperative development of AF 56 .
Importantly, we did not observe an adverse effect from withholding ACEi or ARB. Therefore, on balance, we still recommend that patients withhold their ACEi or ARB preoperatively, especially prior to major surgery in which major fluid shifts, hypotension or large IV fluid requirements are expected. Extra caution should be used in those with heart failure (because of the risk of exacerbating their condition).
A secondary aim of this audit was to collect relevant data and experience to plan for a future clinical trial. The presence of significant confounders in this audit suggests a further observational study is unlikely to yield useful information. Our findings suggest that an adequate time period for drug omission must be used for any future study to allow for adequate drug washout and group discrimination. In addition, the differences between blood pressure in each group were much smaller than was expected. Careful collection of postoperative fluid administration may help discrimination between groups. It may also be important to limit study patients to ASA physical status 3 or 4 patients and major surgery in order to maximise differences between groups and duration of data collection.
In conclusion, this audit found no significant differences in the incidence of hypotension, associated vasopressor or fluid administration, AKI, or AF between patients who had their ACEi/ARB continued or withheld preoperatively. This finding should be interpreted with caution due to the possibility of confounding and an insufficient sample size to adequately compare all variables. As our findings are in contrast to many previous studies, a future prospective adequately powered randomised clinical trial is warranted. 
